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The management of human epidermal growth factor receptor 2-positive (ErbB2þ)b r e a s t
cancer is challenging; patients with ErbB2þ breast tumors have more aggressive disease
and a poor prognosis. The increasing incidence of breast cancer in Asia and the limitations of
existing treatments pose additional challenges. In this review, we summarize the preclinical
and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epi-
dermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly
challenging issues in the management of ErbB2þ breast cancer. These issues are: (i) trastu-
zumab therapy failure, (ii) development of central nervous system metastases, (iii) minimizing
toxicity and (iv) selecting the most appropriate partners (chemotherapy and non-
chemotherapy) for combination therapy with lapatinib. Lapatinib, in combination with
chemotherapeutic agents, such as capecitabine, provides clinical beneﬁts to patients with
ErbB2þ breast cancer, including patients who develop progressive disease on trastuzumab.
Lapatinib, in combination with non-chemotherapeutic agents, such as letrozole, may also
provide a chemotherapy-free treatment option for postmenopausal patients with estrogen
receptor-positive/ErbB2þ metastatic breast cancer. Encouraging results have also emerged
regarding the synergistic effects of lapatinib in combination with other agents for the treatment
of ErbB2þ breast cancer. Promising ﬁndings have also been reported for the use of lapatinib
to prevent and treat central nervous system metastases. Collectively, these results indicate
that the judicious use of lapatinib, an effective oral therapy with a manageable toxicity proﬁle,
can enhance the management of patients with ErbB2þ breast cancer.
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The incidence of breast cancer is increasing in Japan and
many other Asian countries (1). Among Asian women with
breast cancer, an estimated 20% (as determined by immuno-
histochemistry grading of 3þ)t o2 8 %( a sd e t e r m i n e db y
positive ﬂuorescence in situ hybridization) of breast tumors
are human epidermal growth factor receptor 2-positive
(ErbB2þ,H E R 2 þ) (Dr Y. Tan, personal communication,
December 2009). ErbB2þ breast cancer is of clinical
concern, given that these tumors are correlated with more
aggressive disease and a poor prognosis (2–4). Clinical
studies have clearly shown, however, that patients with
ErbB2þ breast cancer can achieve meaningful clinical
beneﬁts from anti-erbB2 therapy (3).
Lapatinib (GW572016) is a unique, orally bioavailable,
small-molecule dual tyrosine kinase inhibitor developed by
GlaxoSmithKline that targets tumor cells overexpressing
both human epidermal growth factor receptor (EGFR;
ErbB1) and ErbB2 tyrosine kinases (5). Lapatinib inhibition
of ErbB1 and ErbB2 kinase activity prevents the activation
of downstream cellular signals that promote tumor cell survi-
val and proliferation (6–8)( F i g .1). Using a rational drug
design approach, more than 3200 quinazoline and
quinazoline-like compounds with potential tyrosine kinase
activity were screened and assayed. Lapatinib was eventually
selected from these compounds as it was a selective and
potent inhibitor of ErbB1 and ErbB2 that had predictable
oral bioavailability and acceptable in vivo toxicity in the tar-
geted patient population (9). First-in-human studies with
lapatinib were initiated in 2001; in 2007 lapatinib was
approved in the USA for use in combination with capecita-
bine for the treatment of ErbB2þ advanced or metastatic
breast cancer in patients who had received previous treat-
ment including an anthracycline, a taxane and trastuzumab
(10)( F i g .2). Additional approvals for this indication have
been granted in 90 more countries, including Japan. The
clinical development of lapatinib is continuing with attention
f o c u s e do nE r b B 2 þ breast cancer as well as other cancers
that overexpress ErbB2.
Although lapatinib provides a new treatment option
for the management of ErbB2þ breast cancer, clinicians
and patients still face a number of clinical challenges,
including: (i) managing trastuzumab failure; (ii) preventing
and managing central nervous system (CNS) metastases;
(iii) minimizing toxicity; and (iv) selecting the most appro-
priate partner for combination therapy with lapatinib.
Figure 1. ErbB2 cellular signaling pathways and lapatinib mechanism of action. ErbB2 (HER2) is a transmembrane tyrosine kinase activated by dimerization
with itself or other ErbB proteins (i.e. ErbB1, ErbB3). Binding of ErbB1 ligands to ErbB1 stimulates heterodimerization with ErbB2 and activation of down-
stream signaling pathways, including PI3K, Akt protein kinase and mTOR, resulting in an increase in cell proliferation. The PTEN protein has tumor suppres-
sor activity in this signaling pathway and loss of PTEN, as well as upregulation of IGF-1R signaling, is associated with trastuzumab resistance. Lapatinib
blocks the activation of the ErbB2 signaling pathway by inhibiting the intracellular tyrosine kinase of ErbB1 and ErbB2 and may circumvent trastuzumab
resistance associated with upregulation of IGF-1R signaling. Lapatinib also binds to the p95 truncated variant of ErbB2 (p95 ErbB2) and inhibits cell prolifer-
ation in trastuzumab-resistant cells expressing p95 ErbB2. ErbB1, human epidermal growth factor receptor 1 (EGFR); ErbB2, human epidermal growth factor
receptor 2 (ErbB2); IGF-1R, insulin-like growth factor-1 receptor; PI3K, phosphatidylinositol-3-kinase; PTEN, Phosphatase and tensin homolog deleted on
chromosome 10; mTOR, mammalian target of rapamycin.
1000 Lapatinib therapy for ErbB2þ breast cancerThe aim of our review is to provide clinicians in Asia
with insight into how lapatinib may help address the clinical
challenges associated with ErbB2þ breast cancer. For each
challenge, we will summarize relevant preclinical and clini-
cal evidence and provide our perspective on what this evi-
dence means to the practicing clinician.
MANAGING TRASTUZUMAB FAILURE:R OLE FOR LAPATINIB?
Trastuzumab has advanced the management of patients
with ErbB2þ metastatic breast cancer; however, 66–
88% of patients treated with trastuzumab as a single agent
and 20–50% of those treated with trastuzumab in combi-
nation therapy do not respond to trastuzumab (i.e. de novo
or primary resistance) (11,12). Further, many patients with
metastatic breast cancer, who initially respond to trastuzu-
mab, develop resistance (i.e. acquired or secondary resist-
ance) and the majority of these patients develop
progressive disease within 1 year of commencing treatment
(13–16). Accumulating preclinical and clinical evidence
suggests that de novo and acquired trastuzumab resistance
in ErbB2þ breast cancer may occur via several different
molecular mechanisms (3,11,17). Clinical data also indi-
cate, however, that patients may beneﬁt from continued
ErbB2 suppression with trastuzumab therapy after tumor
progression on trastuzumab (18–20). Alternatively, evi-
dence also exists that suggests that other anti-erbB2 thera-
pies, such as lapatinib, may provide beneﬁt in patients
with ErbB2þ breast cancers that do not respond to trastu-
zumab therapy (19,21).
PRECLINICAL EVIDENCE:T RASTUZUMAB FAILURE AND LAPATINIB
The potential for lapatinib to inhibit ErbB2-driven tumor
cell growth in trastuzumab-resistant breast cancers has been
investigated in various preclinical studies, including studies
on trastuzumab failure associated with (i) transactivation of
ErbB2 by other tyrosine kinases such as insulin-like growth
factor-1 receptor (IGF-1R); (ii) expression of p95 ErbB2, a
truncated form of ErbB2 lacking the extracellular
trastuzumab-binding domain; and (iii) increase in
phosphatidylinositol-3-kinase (PI3K)/Akt signaling due to
loss of phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN) expression or PI3K catalytic subunit alpha
(PI3KCA) mutation (Fig. 1).
A number of in vitro studies have clearly shown that
ErbB2þ breast cancer cells, rendered trastuzumab-resistant
by long-term exposure to trastuzumab, remain responsive to
lapatinib (22,23). Trastuzumab failure may be mediated, at
least in part, by upregulation of IGF-1R. For example, precli-
nical studies have shown that IGF-1R interaction with ErbB2
is increased in trastuzumab-resistant breast cancer cells
(24,25). Encouragingly, lapatinib was shown to block ErbB2
and IGF-1R crosstalk and inhibit cell growth in a
trastuzumab-resistant breast cancer cell line (23).
Results from preclinical studies also suggest that lapatinib
m a yb ee f f e c t i v ei nt r e a t i n gp 9 5E r b B 2 þ trastuzumab-
resistant breast cancers. Owing to the absence of a
trastuzumab-binding domain on p95 ErbB2, breast tumor
cell lines and tumor xenografts expressing this truncated
variant of ErbB2 appear to be resistant to trastuzumab.
Figure 2. Timeline and history of the preclinical and clinical development of lapatinib. Preclinical development was initiated in 1991 and the ﬁrst-in-human
lapatinib clinical study was conducted in 2001. The proof of concept (POC) milestone to establish a registration indication for lapatinib was achieved in 2003.
Lapatinib received registration approval from the US Food and Drug Administration (FDA) in 2007 for use in combination with capecitabine for the treatment
of ErbB2þ advanced or metastatic breast cancer in patients who had received previous treatment including an anthracycline, a taxane and trastuzumab.
Jpn J Clin Oncol 2010;40(11) 1001In vitro and in vivo studies have demonstrated that lapatinib
can effectively inhibit the growth of trastuzumab-resistant
breast cancer cell lines and tumor xenografts that express
p95 ErbB2, presumably because lapatinib targets the intra-
cellular tyrosine kinase component of ErbB2 (26).
Trastuzumab resistance may also be mediated in some
ErbB2þ breast tumors by an increase in PI3K/Akt signaling
associated with either the loss or inactivation of PTEN
expression or PI3KCA mutation (17,27). Presence of PTEN
is associated with tumor suppressor activity (17). Loss of
PTEN appears to counteract the anti-tumor effects of trastu-
zumab by promoting PI3K/Akt activation, which, in turn,
stimulates tumor cell growth (17). In vitro studies in
PTEN-deﬁcient ErbB2þ breast tumor cell lines showed that
tumor cells remained responsive to lapatinib and that lapati-
nib sensitivity appeared to be PTEN-independent (28).
Transfection of ErbB2-overexpressing cell lines with mutant
PI3KCA or wild-type PI3KCA resulted in trastuzumab resist-
ance, suggesting that activation of the PI3K signaling
pathway by PI3KCA mutation appeared to mediate resistance
(27). Further, oncogenic mutations of PI3KCA, identiﬁed in
several different ErbB2þ human breast cancer cell lines, are
associated with trastuzumab resistance in vitro (29). Contrary
to earlier preclinical ﬁndings that showed that lapatinib sen-
sitivity was PTEN-independent, a recent in vitro study has
shown that hyperactivation of the PI3K pathway by either
loss-of-function mutations in PTEN or PI3KCA mutation
may also confer resistance to lapatinib in breast cancer cell
lines (30). Another recent in vitro study found that isolated
clones of ErbB2þ breast cancer cell lines with acquired
resistance to lapatinib were also cross-resistant to trastuzu-
mab and exhibited increased expression of AXL, a receptor
tyrosine kinase (31). This ﬁnding suggests that upregulation
of AXL may be a novel mechanism involved in the develop-
ment of lapatinib and trastuzumab resistance. Additional pre-
clinical studies are required to determine the role of PI3K
activation and AXL upregulation in modulating lapatinib and
trastuzumab resistance.
Lapatinib has yet to be investigated in other molecular
mechanisms of trastuzumab resistance, such as
MUC4-mediated resistance. Preclinical studies have shown
that the overexpression of the membrane-bound mucin glyco-
protein, MUC4, in a trastuzumab-resistant human cell
line, interferes with the binding of trastuzumab to ErbB2 (32).
Tumors that overexpress MUC4 may potentially promote
tumorigenesis by activating ErbB2, suppressing apoptosis and
inhibiting immune recognition of tumor cells (11,33).
Collectively, the results from these and other preclinical
studies provided a strong scientiﬁc rationale for the conduct
of clinical studies with lapatinib in patients with
trastuzumab-resistant ErbB2þ breast cancer.
CLINICAL EVIDENCE:T RASTUZUMAB FAILURE AND LAPATINIB
Clinical evidence from a recent systematic review of obser-
vational studies (18) and a randomized clinical trial (20)
suggest that patients with breast tumors that progress on tras-
tuzumab treatment may still beneﬁt from continued ErbB2
suppression with trastuzumab (19). However, accumulating
clinical data also indicates that treatment with other
anti-erbB2 therapies, such as lapatinib, may also improve
clinical outcomes in this patient population (19,34). Several
clinical trials have been undertaken to examine the effect of
lapatinib in patients with trastuzumab-resistant ErbB2þ
breast cancer (19,35,36). The pivotal EGF100151 study
(Table 1)( 36), was a Phase III, randomized, controlled trial
of 399 patients with ErbB2þ locally advanced or metastatic
progressive disease. Patients were randomized to lapatinib
plus capecitabine or to capecitabine alone. Treatment with
lapatinib plus capecitabine signiﬁcantly increased time to
progression (TTP), compared with capecitabine alone (6.2
versus 4.3 months, respectively; hazard ratio [HR; 95%
CI] ¼ 0.57; 0.43–0.77; P , 0.001; Fig. 3). Signiﬁcant differ-
ences in the overall response rate (ORR: 24 versus 14%;
odds ratio [OR, 95% CI] ¼ 1.9, 1.1–3.4; P ¼ 0.017) and
clinical beneﬁt rate (CBR: 29 versus 17%; [OR, 95% CI] ¼
2.0, 1.2–3.3; P ¼ 0.008) were observed (36). An exploratory
subgroup analysis was also completed to assess the effect of
the extent of pretreatment on TTP and overall survival (OS)
(34,37). Among patients pretreated with fewer than three
regimens, both TTP and OS were signiﬁcantly greater for
those treated with lapatinib plus capecitabine compared with
capecitabine alone (TTP: 49.4 versus 19.7 weeks, respect-
ively, [HR, 95% CI] ¼ 0.37, 0.18–0.77; P ¼ 0.006; OS:
87.3 versus 55.1 weeks, respectively, [HR, 95% CI] ¼ 0.51,
0.30–0.86; P ¼ 0.009). Among patients pretreated with
more than three regimens, TTP, but not OS, was signiﬁcantly
greater for those treated with lapatinib plus capecitabine
compared with capecitabine alone (TTP: 25.4 versus 18.6
weeks, respectively, [HR, 95% CI] ¼ 0.59, 0.43–0.82; P ¼
0.001; OS: 71.4 versus 66.6 weeks, respectively, [HR, 95%
CI] ¼ 0.95, 0.76–1.21; P ¼ 0.7) (34,37). These ﬁndings
indicate that lapatinib plus capecitabine was superior to
capecitabine alone in patients whose disease had progressed
on trastuzumab and that less heavily pretreated patients had
the greatest beneﬁt in terms of improved TTP and OS com-
pared with more heavily pretreated patients. The results from
the EGF100151 trial facilitated registration approval for the
use of lapatinib in combination with capecitabine to treat
patients with ErbB2þ breast cancer whose disease has pro-
gressed after treatment with trastuzumab-based regimens.
Lapatinib, as monotherapy, has been investigated in
several clinical studies in patients with trastuzumab-naı ¨ve or
trastuzumab-refractory ErbB2þ locally advanced or meta-
static breast cancer (38–41). Clinical ﬁndings in these
studies suggest that lapatinib monotherapy had anti-tumor
activity in both trastuzumab-naive and trastuzumab-
refractory patient populations and that the treatment was
well-tolerated (38–41). Lapatinib, in combination with tras-
tuzumab, was also assessed in a randomized clinical study of
296 patients with trastuzumab-refractory ErbB2þ metastatic
breast cancer (35,42). In this study (EGF104900 study;
1002 Lapatinib therapy for ErbB2þ breast cancerTable 1), lapatinib plus trastuzumab signiﬁcantly improved
median OS, compared with lapatinib alone (60.7 versus 41.4
weeks; [HR, 95% CI ¼ 0.74, 0.57–0.97; P ¼ 0.026) in
patients heavily pretreated with trastuzumab (35). These
clinical beneﬁts reinforce the merit of continued ErbB2 sup-
pression and dual blockade of ErbB2 after disease
progression.
Consistent with preclinical ﬁndings, clinical studies have
shown that truncation of the extracellular domain of ErbB2
(p95 ErbB2), loss of PTEN expression, or PI3KCA
mutations in ErbB2þ breast cancer is associated with a poor
response to trastuzumab and may be markers for trastuzumab
failure (17,26,43). Further support for a role for lapatinib in
the management of patients with trastuzumab failure comes
from a clinical study of patients with ErbB2þ breast tumors
expressing low PTEN or PI3KCA mutations (43). This study
showed that low PTEN expression or PI3KCA mutation was
correlated with trastuzumab, but not lapatinib, resistance
(43). This clinical ﬁnding is discordant with recent preclini-
cal evidence that suggests that loss-of-function mutations in
PTEN or PI3KCA mutations could confer lapatinib resist-
ance in ErbB2þ human breast cancer cell lines (30). The
Table 1. Phase III trials of lapatinib plus chemotherapy or non-chemotherapy agents for locally advanced or metastatic breast cancer
Reference Patient population Therapy N Outcomes
Lapatinib plus chemotherapy agents




399 TTP: 6.2 versus 4.3 months; HR (95% CI): 0.57 (0.43–
0.77); P , 0.001
CBR: 29 versus 17%; OR (95% CI): 2.0 (1.2–3.3);
P ¼ 0.008
ORR: 24 versus 14%; OR (95% CI): 1.9 (1.1–3.4);
P ¼ 0.017
OS: 15.6 versus 15.3 months; HR (95% CI): 0.78 (0.55–
1.12); P ¼ 0.177
Di Leo et al. (74). (EGF30001) First-line MBC Lapatinib þ paclitaxel
versus
placebo þ paclitaxel
579 ErbB2þ subgroup (n ¼ 86)
TTP: 36.4 versus 25.1 weeks; HR (95% CI): 0.53 (0.31–
0.89); P ¼ 0.005
CBR: 69.4 versus 40.5%; OR (95% CI): 3.5 (1.3–9.7);
P ¼ 0.011
ORR: 63.3 versus 37.8%; OR (95% CI): 3.0 (1.1–8.5);
P ¼ 0.023
OS: 104.6 versus 82.4 weeks; HR (95% CI): 0.74 (0.4–
1.4); P ¼ 0.365
Lapatinib plus non-chemotherapy agents
Johnston et al. (66) (EGF30008) First-line MBC Lapatinib þ letrozole
versus
placebo þ letrozole
1286 Primary population: ErbB2þ (n ¼ 219)
PFS: 8.2 versus 3.0 months; HR (95% CI): 0.71 (0.53–
0.96); P ¼ 0.019
CBR: 48 versus 29%, OR (95% CI): 0.4 (0.2–0.8);
P ¼ 0.003
ORR: 28 versus 15%, OR (95% CI): 0.4 (0.2–0.9);
P ¼ 0.021
OS: 33.3 versus 32.3 months; HR (95% CI): 0.74 (0.5–
1.1); P ¼ 0.113
O’Shaughnessy et al. (42);
Blackwell et al. (35)
(EGF104900)
ErbB2þ, MBC Lapatinib þ trastuzumab
versus lapatinib
296 PFS: 12.0 versus 8.1 weeks; HR (95% CI): 0.73 (0.57–
0.93); P ¼ 0.008
CBR: 24.7 versus 12.4%, OR (95% CI): 2.2 (1.2–4.5);
P ¼ 0.020
ORR: 10.3 versus 6.9%, OR (95% CI): 1.5 (0.6–3.9);
P ¼ 0.46
OS: 60.7 versus 41.4 weeks; HR (95% CI): 0.74 (0.57–
0.97); P ¼ 0.026
CBR, clinical beneﬁt rate; CI, conﬁdence interval; ErbB2þ, human epidermal growth factor receptor 2-positive; HR, hazard ratio; LABC, locally advanced
breast cancer; MBC, metastatic breast cancer; OR, odds ratio; ORR, overall response rate; OS, overall survival PFS, progression-free survival; TTP, time to
progression.
Jpn J Clin Oncol 2010;40(11) 1003lack of a validated clinical test to identify patients with low
PTEN tumors and relatively low patient numbers may poten-
tially have limited the ﬁndings in the clinical study. Further
clinical studies using a validated measure of PTEN
expression in ErbB2þ breast tumors are required to better
establish a potential correlation between low PTEN and
resistance to lapatinib (30).
Given the promising ﬁndings from preclinical studies, the
role of concomitant inhibition of the IGF-1R and ErbB2 sig-
naling pathways is currently being investigated in a Phase II
study in patients with trastuzumab-resistant locally advanced
or metastatic ErbB2þ breast cancer (44). Patients will be
treated with lapatinib plus capecitabine with or without the
anti-IGF-1R monoclonal antibody, cixutumumab (IMC-
A12). The primary endpoint will be progression-free survival
(PFS) (45). This study should provide timely and critical
insight into whether lapatinib plus capecitabine can over-
come IGF-1R-mediated trastuzumab failure.
On the basis of the results from preclinical and clinical
studies, lapatinib, may have an important role in improving
the management of ErbB2þ trastuzumab-resistant progress-
ive disease.
PREVENTING AND MANAGING CNS METASTASES IN ERBB2þ
BREAST CANCER
Preventing and managing CNS metastases has emerged as
an increasingly important clinical challenge for clinicians
treating patients with ErbB2þ breast cancer. Approximately
25–50% of trastuzumab-treated patients will develop CNS
metastases (46,47). Currently, those who develop CNS
metastases have few effective treatment options available.
Systemic chemotherapy, surgery (including stereotactic
radiosurgery), whole brain radiotherapy and continued
trastuzumab therapy provide some improvement in OS;
however, the median time from the diagnosis of CNS metas-
tases to death is only 4–15 months (46–48). On the basis of
comparisons with historical controls (i.e. patients treated in
the pretrastuzumab era), there has been an apparent increase
in the incidence of CNS metastases in trastuzumab-treated
patients with ErbB2þ breast cancer (46,47,49). Several
hypotheses have been suggested for the observed increase in
CNS metastases in this patient population, including:
(i) ErbB2þ tumors appear to have a more aggressive
phenotype and are more likely to metastasize to the
CNS (49–51);
(ii) The availability of trastuzumab therapy has resulted in
better control of systemic disease, which has increased
survival, but paradoxically, has also increased the
opportunity for CNS metastases to develop (46); and
(iii) The blood-brain barrier (BBB) may create a ‘sanctu-
ary’ site in the CNS by preventing systemic
anti-cancer agents from entering the CNS, thus, allow-
ing ErbB2þ tumors to colonize and grow (46,52)
Trastuzumab’s large molecular size prevents the antibody
from crossing the BBB and inhibiting the growth of ErbB2þ
CNS tumors. In patients treated with trastuzumab, the ratio
of trastuzumab levels in serum to trastuzumab levels in cere-
brospinal ﬂuid was 420:1. After whole brain radiotherapy,
this ratio was reduced to 76:1, suggesting that the BBB was
still an effective barrier to trastuzumab, even though the
barrier was somewhat impaired by radiotherapy (53).
Although systemic disease appears to be responsible for
the lower survival rates in patients with ErbB2þ breast
cancer in the pretrastuzumab era, the use of trastuzumab has
altered the clinical course of the disease (46,47). Thus, with
improved systemic control, the treatment of CNS disease is
Figure 3. Time to progression (TTP) in patients with ErbB2þ breast cancer treated with lapatinib plus capecitabine compared with capecitabine alone
(EGF100151 study). Data include the intent-to-treat population of patients with ErbB2þ, trastuzumab-resistant, locally advanced or metastatic breast cancer.
Five patients with competing risk were censored. Figure adapted and reprinted from the publication by Cameron et al. (36) with kind permission from
Springer Science þ Business media.
1004 Lapatinib therapy for ErbB2þ breast cancernow a clinically relevant issue that requires effective proac-
tive management.
Lapatinib is a logical candidate to assess in clinical
studies for the treatment and prevention of CNS metastases
in patients with ErbB2þ breast cancer because of its potent
anti-erbB2 activity and its small molecular size. Preclinical
and clinical studies indicate that lapatinib can penetrate the
BBB and exert an anti-tumor effect in the CNS.
PRECLINICAL EVIDENCE: CNS METASTASES IN ERBB2þ BREAST
CANCER AND LAPATINIB
The recent development of an in vivo mouse model of
ErbB2þ brain metastases has helped researchers gain new
insights into the cellular and molecular mechanisms involved
in CNS metastases (51). Further, this model has proven to be
a valuable tool to assess novel therapies that may inhibit the
colonization and growth of ErbB2þ tumor cells within the
brain. To develop this model, a brain-seeking derivate of a
human breast cancer cell line overexpressing ErbB1
(MDA-MB-231) was transfected with an ErbB2-expressing
vector (231-BR-HER2) or with an empty control vector
(231-BR-vector) (51). After intracardiac injection of
231-R-ER2 or 231-BR-vector cells into BALB/c nude mice,
metastatic brain lesions were shown to form 20 to 25 days
later. Compared with 231-BR-vector control cells overex-
pressing only ErbB1, 231-BR-HER2 cells overexpressing
ErbB1/ErbB2 showed a 2.5- to 3.0-fold increase in coloniza-
tion (i.e. large metastases: .300 microns in any single
dimension) in the brain. These ﬁndings suggest that
ErbB2 expression plays an important role in promoting the
growth of these cells and the development of brain metas-
tases (51).
Administration of 30 or 100 mg/kg lapatinib 5 days after
injection of cells in this mouse model signiﬁcantly decreased
the total number of large metastases detected in the brains of
mice injected with 231-BR-HER2 cells by 50–53% (P ,
0.001) (Fig. 4)( 54). Further, lapatinib also decreased the
number of large metastases in the ErbB1-overexpressing
control cells, but only at the highest dose tested. In vitro,
lapatinib was shown to inhibit cell proliferation and
migration, as well as block the phosphorylation of ErbB1
and ErbB1/ErbB2 in 231-BR-vector control and
231-BR-HER2 brain-seeking breast cancer cell lines,
respectively (54). Taken together, these results indicate that
lapatinib may prevent the proliferation of ErbB2þ breast
cancer cells in the brain.
CLINICAL EVIDENCE: CNS METASTASES IN ERBB2þ BREAST
CANCER AND LAPATINIB
A potential role for lapatinib in reducing CNS metastases
was ﬁrst apparent from an exploratory analysis of data from
a Phase III study of lapatinib plus capecitabine versus cape-
citabine alone in patients with advanced ErbB2þ breast
cancer (EGF100151) (36,55). This analysis showed that lapa-
tinib plus capecitabine treatment was associated with a lower
rate of CNS tumor progression, compared with capecitabine
alone (2% [n ¼ 4] versus 6% [n ¼ 13], respectively; P ¼
0.045 (36).
This ﬁnding raised interest in the results from an explora-
tory analysis of data from a Phase II pilot study of lapatinib
monotherapy in 39 patients with ErbB2þ breast cancer
who had CNS metastases (56). This analysis showed that
lapatinib treatment was associated with a decrease in tumor
volume in some patients. Of the 34 patients analyzed,
Figure 4. Lapatinib inhibition of metastatic colonization of mouse brain by ErbB2-positive human breast cancer cells in a mouse model of brain metastases.
Human breast cancer cells expressing ErbB1/ErbB2 (231-BR-HER2) or ErbB1 (231-BR-vector) and enhanced green ﬂuorescent protein (EGFP) were adminis-
tered by intracardiac injection into the left ventricle of BALB/c nude mice. Five days after injection mice were administered lapatinib (30 or 100 mg/kg body
weight) or vehicle twice-daily for 24 days by oral gavage. Brains were dissected at necropsy and imaged to detect EGFP expression in metastases derived
from the injected 231-BR cells. Representative dorsal whole brain images from two mice in each treatment group are shown. Image reprinted from the publi-
cation entitled “Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain” by Gril et al. (54) with permission from Oxford University
Press. ErbB1, human epidermal growth factor receptor 1; ErbB2, human epidermal growth factor receptor 2.
Jpn J Clin Oncol 2010;40(11) 10053 (9%) patients achieved at least a 50% reduction in CNS
tumor volume and 7 (21%) patients achieved at least a 10–
30% reduction in CNS tumor volume (56). A larger Phase II
study (EGF105084) was conducted to investigate the effects
of lapatinib monotherapy on CNS tumor volume in 242
patients with ErbB2þ breast cancer whose CNS tumors had
progressed after trastuzumab therapy and cranial radiother-
apy (57). Of the 200 patients in this study with available
data, 19 (8%) patients had at least a 50% reduction in tumor
volume and 50 (21%) patients had at least a 20% reduction
in tumor volume (57).
Given the ﬁndings from the two Phase II studies and the
results from the large Phase III lapatinib plus capecitabine
registration trial (EGF100151), an extension to the
EGF105084 study was deemed appropriate. In the extension
phase, patients with ErbB2þ breast cancer whose CNS
disease had progressed on lapatinib monotherapy were
treated with lapatinib plus capecitabine (57). Findings from
this study indicate that lapatinib plus capecitabine treatment
was associated with a reduction in the volume of brain
metastases. Of the 50 patients who entered the extension
phase, 10 (20%, 95% exact CI: 3.0–33.7) patients had an
objective CNS response. Further, 11 (22%) patients had at
least a 50% reduction in tumor volume and 20 (40%)
patients had at least a 20% reduction in tumor volume (57).
More recently, lapatinib plus capecitabine was evaluated
in a lapatinib expanded access program (LEAP) and a
French Authorisation Temporaire d’Utilisation (ATU)
program for ErbB2þ breast cancer patients with CNS metas-
tases (58). These programs provided patients with an oppor-
tunity to receive lapatinib after regulatory approval, but
before the agent was commercially available. Preliminary
analyses of the LEAP/ATU data also suggest that lapatinib
plus capecitabine had anti-tumor activity in patients with
CNS metastases. Of the 138 patients with progressive
disease, 3 (2%) had a complete CNS response and 22 (16%)
had a partial CNS response (58). Several other clinical trials
are now underway to assess the role of lapatinib in prevent-
ing or treating CNS metastases in patients with ErbB2þ
breast cancer (Table 2); the results of these studies are
eagerly awaited.
In summary, preclinical and clinical studies have yielded
promising results regarding the role that lapatinib may have
in preventing and managing CNS metastases in patients with
ErbB2þ breast cancer.
MINIMIZING TOXICITY:T HE PROMISE OF CHEMOTHERAPY-FREE
REGIMENS
Minimizing the adverse outcomes and toxicity associated
with the use of chemotherapeutic treatments is a challenge
for both clinicians and patients. These adverse outcomes
increase the cost and complexity of care and reduce the
patient’s quality of life (59). With advances in our under-
standing of the pathophysiology of ErbB2þ breast cancer,
we are now able to consider whether ErbB2þ breast cancer
could be managed with chemotherapy-free regimens such as
lapatinib plus trastuzumab (as previously described) or lapa-
tinib plus letrozole. This is an exciting possibility for clini-
cian and patient alike. Preclinical and clinical evidence
indicate that this possibility may be achieved for selected
patients through the use of therapies that target more than
Table 2. Ongoing clinical trials to assess the role of lapatinib in preventing or treating central nervous system metastases in patients with early or advanced/









Double-blind, RCT, lapatinib versus placebo III 3000 18: DFS
No trastuzumab 28: OS, CNS RFI
NCT00490139 (EGF106708,
BIG 2-06, ALTTO)
BC, adjuvant Open label, RCT, lapatinib versus trastuzumab
versus trastuzumab followed by lapatinib versus
lapatinib þ trastuzumab
III 8000 18: DFS






Open label, RCT, lapatinib versus trastuzumab
versus lapatinib þ trastuzumab
III 450 18: DFS




Stage IV MBC Open label, RCT, lapatinib þ paclitaxel or
docetaxel versus trastuzumab þ paclitaxel or
docetaxel
III 600 18: PFS




Stage IV MBC Open label, RCT, lapatinib þ capecitabine versus
trastuzumab þ capecitabine
III 650 18: Incidence of CNS metastases as
ﬁrst site of progression
aStudy identiﬁcation codes for trials registered in the National Institutes of Health Clinical Trials Registry (http://clinicaltrials.gov, accessed 5 November
2009). BC, breast cancer; 18, primary endpoint; 28, secondary endpoint(s); CBR, clinical beneﬁt rate; CNS, central nervous system; CNS RFI, central nervous
system recurrence-free intervals; DFS; disease-free survival; MBC, metastatic breast cancer; OS, overall survival; PFS, progression-free survival; RCT,
randomized controlled trial; TTDR, time to distant recurrence; TTR, time to recurrence.
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targeted therapies, such as lapatinib and anti-estrogens, could
not only yield clinical beneﬁts, but could also help overcome
the problem of endocrine therapy resistance.
PRECLINICAL EVIDENCE:C HEMOTHERAPY-FREE REGIMENS AND
LAPATINIB
Preclinical studies support the rationale for pursuing
chemotherapy-free treatments for breast cancer; these studies
have shown that lapatinib can have additive or synergistic
inhibitory effects when combined with anti-estrogen therapies.
Results from in vitro studies on breast cancer cell lines
demonstrate that lapatinib and tamoxifen can cause a faster
and more profound inhibition of cell cycle progression than
tamoxifen alone (60). The synergistic effects of lapatinib and
tamoxifen treatment were reﬂected in a greater increase in
p27 and a greater decrease in cyclin D1 and cyclin E-cdk2
activity, relative to the effect of either drug alone (60).
Results from in vitro studies with lapatinib plus fulvestrant
have shown that these agents can additively or synergistically
inhibit the growth of breast cancer cell lines (31). Lapatinib
plus fulvestrant have been shown to promote G1-S blockade
and increase apoptosis in an additive manner (61). Together,
lapatinib and fulvestrant decreased the expression levels of
Bcl-2 and survivin and increased the expression levels of p21
and p27 (61). Lapatinib plus fulvestrant have also been shown
to synergistically inhibit the growth of a number of breast
cancer cell lines through the downregulation of cell signaling
proteins, such as p-PDK1, ERK1/2 and p-ERK (62).
As ErbB2þ tumors have an increased resistance to endo-
crine therapy, compared with ErbB2-negative (ErbB2–)
tumors (31,63), much attention has focused on whether
anti-ErbB2 therapies might restore or enhance sensitivity to
endocrine therapies. The molecular crosstalk between the
estrogen receptor (ER) and the ErbB1/ErbB2 signaling path-
ways may contribute to endocrine resistance (64)( F i g .5).
Therefore, treatments that interfere with the ErbB1/ErbB2
signaling pathway, such as lapatinib, have the potential to
modify ER and ErbB crosstalk and subsequently restore sen-
sitivity to endocrine therapy. Results from preclinical studies
support this hypothesis. Lapatinib and tamoxifen effectively
inhibited the growth of tamoxifen-resistant breast cancer
xenograft tumors in vivo; both the rate and volume of tumor
growth were reduced with combined treatment (60).
Lapatinib in combination with estrogen deprivation also
effectively blocked the growth of lapatinib-resistant ErbB2þ
breast cancer cell colonies (31).
Collectively, the results from in vitro and in vivo preclini-
cal studies have provided strong justiﬁcation for clinical
Figure 5. Molecular crosstalk between the ER and ErbB1/ErbB2 cellular signaling pathways in endocrine-resistant ErbB2-positive breast cancer cells.
Estrogen bound to the ER activates estrogen-regulated genes via a classical signaling pathway. ErbB1/ErbB2 stimulation by growth factors results in activation
of the PI3K/Akt and MAPK signaling pathways, leading to tumor cell growth. Long-term tamoxifen therapy may promote endocrine resistance via bidirec-
tional crosstalk between the ER and growth factor receptor (i.e. IGF-1R or ErbB1/ErbB2) signaling pathway components. Bidirectional activation of these
pathways promotes ER phosphorylation and ER target gene transcription as well as ErbB1/ErbB2/MAPK-mediated signaling and IGF-1R-mediated PI3K/Akt
growth signaling pathways. Modulation of these pathways by combined use of lapatinib and anti-estrogen therapy (e.g. letrozole) may overcome endocrine
resistance. CBP, cAMP response element binding protein (CREB)-binding protein; ER, estrogen receptor; ErbB1, human epidermal growth factor receptor 1;
ErbB2, human epidermal growth factor receptor 2; mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; P, phosphate; p90
RSK,
p90 ribosomal S6 kinase; p160, p160 steroid receptor co-activator protein(s); PI3K, phosphatidylinositol-3-kinase; PTEN, phosphatase and tensin homologue
deleted on chromosome 10; RAF, murine leukemia viral oncogene homologue 1; SOS, son-of-seven less guanine nucleotide exchange factor. Figure adapted
from the publication by Johnston (64) (Fig. 1) with permission from the American Association for Cancer Research.
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mens, such as anti-estrogens plus lapatinib, for treating
ErbB2þ breast cancer.
CLINICAL EVIDENCE:C HEMOTHERAPY-FREE REGIMENS AND
LAPATINIB
Currently, treatment guidelines do not recommend the use of
targeted treatment regimens for the management of
ER-positive (ERþ)/ErbB2þ breast cancer, except for
patients with visceral crisis (65) .T h er e s u l t sf r o man u m b e r
of completed (Table 1) and ongoing (Table 3) clinical trials
may justify changes to treatment guidelines and clinical
practice. For example, recent results from the EGF30008
clinical trial (66)( T a b l e1) support the use of a ﬁrst-line
chemotherapy-free treatment regimen for postmenopausal
women with ERþ/ErbB2þ metastatic breast cancer. In this
Phase III, randomized, double-blind, placebo-controlled trial,
trastuzumab-naı ¨ve patients with either ErbB2þ or ErbB22
metastatic breast cancer (N ¼ 1286) received either lapatinib
plus letrozole or letrozole plus placebo. The primary end-
point was PFS (as assessed by the investigator) in the ERþ/
ErbB2þ population (n ¼ 219). In this primary outcome
population, treatment with lapatinib plus letrozole
Table 3. Ongoing clinical trials of lapatinib combination therapy for early or advanced/metastatic breast cancer
Study
a Patient population Study design and treatment regimen Phase N
Lapatinib plus chemotherapy agents
NCT00753207 Relapsed stage III/IV BC
b Open label, dose escalation to MTD, lapatinib þ epirubicin I 24
NCT00513058 ErbB2þ relapsed stage III/IV
BC
Open label, dose escalation to MTD, lapatinib þ vinorelbine I 60
NCT00614978 (LAPTEM) ErbB2þ relapsed brain
metastases in BC
Open label, dose escalation to MTD, lapatinib þ temozolamide I 18
NCT00477464 (109749) Japanese ErbB2þ
trastuzumab-failed MBC
Open label, single-arm, lapatinib þ capecitabine II 50
NCT00313599 ErbB2þ relapsed stage III/IV
solid tumor
Open label, dose escalation to MTD, lapatinib þ Nab-paclitaxel I 22
NCT00709761 ErbB2þ second-line MBC Open label, single-arm, lapatinib þ Nab-paclitaxel II 60
NCT00331630 ErbB2þ BC, neoadjuvant Open label, pilot study, lapatinib þ Nab-paclitaxel II 30
NCT00756470 ErbB2þ inﬂammatory BC,
neoadjuvant
Open label, single-arm, lapatinib þ paclitaxel then
lapatinib þ ﬂuorouracil þ epirubicin þ cyclophosphamide
II 60
NCT00404066 ErbB2þ BC, neoadjuvant Open label, single-arm, doxorubicin þ cyclophosphamide then
lapatinib þ docetaxel
II 72
Lapatinib plus chemotherapy and non-chemotherapy agents
NCT00632489 Relapsed stage III/IV solid
tumor
b
Open label, dose escalation to MTD in three arms,
lapatinib þ LBH589 versus LBH589 þ capecitabine versus
lapatinib þ LBH589 þ capecitabine
I5 5
NCT00820872 ErbB2þ BC, adjuvant Open label, single-arm,
lapatinib þ docetaxel þ carboplatin þ trastuzumab
II 33
NCT00841828 ErbB2þ BC, neoadjuvant Open label, RCT,
lapatinib þ epirubicin þ cyclophosphamide þ docetaxel versus
trastuzumab þ epirubicin þ cyclophosphamide þ docetaxel
II 102
NCT00769470 ErbB2þ BC, neoadjuvant Open label, RCT, lapatinib þ carboplatin þ docetaxel versus
trastuzumab þ carboplatin þ docetaxel versus
lapatinib þ trastuzumab þ carboplatin þ docetaxel
II 140
NCT00684983 (45) ErbB2þ ﬁrst-line or relapsed
MBC
Open label, RCT, lapatinib þ capecitabine þ IMC-A12 versus
lapatinib þ capecitabine
II 154
NCT00770809 (CALGB 40601) ErbB2þ BC, neoadjuvant Open label, RCT, lapatinib þ paclitaxel versus
trastuzumab þ paclitaxel versus




ErbB2þ stage IV MBC Open label, RCT, lapatinib þ paclitaxel or docetaxel versus








1008 Lapatinib therapy for ErbB2þ breast cancersigniﬁcantly increased PFS, compared with letrozole plus
placebo (8.2 versus 3.0 months, respectively; [HR, 95%
CI] ¼ 0.71, 0.53–0.96; P ¼ 0.019). Signiﬁcant differences
were also apparent in this population for the ORR (28 versus
15%, P ¼ 0.021) and CBR (48 versus 29%, P ¼ 0.003).
There was no signiﬁcant difference in OS between the two
regimens (33.3 versus 32.3 months, P ¼ 0.113); however, at
the time of publication of these data, ,50% of the OS
events had been recorded. In the intent-to-treat (ITT) popu-
lation, there was a modest, but signiﬁcant, increase in PFS
(11.9 versus 10.8 months [HR, 95% CI] ¼ 0.86, 0.76–0.98;
P ¼ 0.026) (66). Exploratory analyses examining the effect
of early (more than 6 months before study entry) versus
recent (,6 months before study entry) tamoxifen discontinu-
ation on clinical outcomes were also completed for the
ERþ/ErbB22 population of patients. These analyses
showed a trend toward improved PFS and CBR in the lapati-
nib plus letrozole arm, compared with the letrozole plus
placebo arm, for those patients who had ceased tamoxifen
,6 months before study entry (PFS: 8.3 versus 3.1 months,
respectively, P ¼ 0.117; CBR: 44 versus 32%, respectively).
This trend was not observed in the subpopulation of patients
who had ceased tamoxifen more than 6 months before study
entry (PFS: 14.7 versus 15.0 months, P ¼ 0.522; CBR: 62
versus 64%). Although the difference did not reach statistical
signiﬁcance, these ﬁndings suggest a potential beneﬁt for
combination treatment with lapatinib plus letrozole for
patients with ERþ/ErbB22 breast cancer who develop
tamoxifen resistance early during adjuvant treatment with
tamoxifen (66). Results from the safety analyses of the ITT
population in the EGF30008 trial showed that adverse events
were similar and manageable between the two treatment
regimens. The most common adverse events were diarrhea,
rash, nausea, arthralgia and fatigue (66). Treatment guide-
lines for the management of lapatinib-associated toxicities
(primarily diarrhea and rash) are now available (67–71). As
clinical experience with lapatinib has increased, clinicians
are now able to manage these toxicities more effectively in
their routine clinical practice.
The efﬁcacy and safety results from this major clinical
trial indicate that concurrent inhibition of ER and ErbB2
could indeed provide a new, oral, chemotherapy-free
Table 3. Continued
Study
a Patient population Study design and treatment regimen Phase N
NCT00567554 (GepaQuinto) ErbB2þ BC, neoadjuvant Open label, RCT,
lapatinib þ epirubicin þ cyclophosphamide þ docetaxel versus
trastuzumab þ epirubicin þ cyclophosphamide þ docetaxel versus
bevacizumab þ epirubicin þ cyclophosphamide þ docetaxel
versus epirubicin þ cyclophosphamide þ docetaxel versus
paclitaxel
III 2547
Lapatinib plus non-chemotherapy agents
NCT00352443 Relapsed stage III/IV solid
tumor
b
Open label, dose escalation to MTD, lapatinib þ everolimus I 48




b Open label, single-arm, lapatinib þ tamoxifen II 41
NCT00548184 ErbB2þ BC, neoadjuvant Double-blind RCT, lapatinib þ trastuzumab þ endocrine therapy
versus lapatinib þ trastuzumab
II 64
NCT00390455 (CALGB 40302) First-line or relapsed advanced
BC
b






Double-blind, RCT, lapatinib þ fulvestrant versus
placebo þ fulvestrant versus lapatinib þ aromatase




ErbB2þ BC, neoadjuvant Open label, RCT, lapatinib versus trastuzumab versus
lapatinib þ trastuzumab; addition of paclitaxel for all treatment
arms after 6 weeks
III 450
NCT00486668 (NSABP B-41) ErbB2þ BC, neoadjuvant Open label, RCT, lapatinib þ AC þ paclitaxel versus
trastuzumab þ AC þ paclitaxel versus




ErbB2þ BC, adjuvant Open label, RCT, lapatinib versus trastuzumab versus trastuzumab
then lapatinib versus lapatinib þ trastuzumab
III 8000
AC, doxorubicin þ cyclophosphamide; BC, breast cancer; ErbB2þ, human epidermal growth factor receptor 2-positive; MBC, metastatic breast cancer; MTD,
maximum tolerated dose; RCT, randomized controlled trial.
aStudy identiﬁcation codes for trials registered in the National Institutes of Health Clinical Trials Registry (http://clinicaltrials.gov, accessed 5 November
2009).
bPatient population ErbB2 status unknown.
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static breast cancer. Clinical acumen would still be
required, however, to determine the most appropriate treat-
ment strategy for each patient. Clinicians would need to
take patient-related factors into account, such as the rela-
tive resistance to endocrine therapy, age, symptom status,
rate of disease progression, tumor burden and extent of
visceral disease.
SELECTING THE MOST APPROPRIATE PARTNERS FOR COMBINATION
THERAPY WITH LAPATINIB
In an ideal world, clinicians would be able to review evi-
dence from head-to-head comparator trials in different
patient populations to help them select the most appropriate
combination treatment regimen for each particular patient. In
the real world, clinicians have to take several factors into
account when deciding on which combinations of che-
motherapeutic and non-chemotherapeutic agents are most
appropriate for a particular patient. These factors might
include synergy between agents, non-overlapping toxicity
proﬁles, non-cross-resistant mechanisms of action, previous
treatment exposure, generalizability of clinical data and
affordability. These factors will likely also inﬂuence a clini-
cian’s choice of lapatinib-containing combination therapies
that have been shown to be of clinical beneﬁt in speciﬁc
patient populations.
PRECLINICAL EVIDENCE:C OMBINATION THERAPY WITH LAPATINIB
Given lapatinib’s targeted mechanism of action on ErbB1/
ErbB2, preclinical studies have also been conducted to
investigate the efﬁcacy of lapatinib when partnered with
either chemotherapy or other targeted non-chemotherapy
agents. In the ErbB2þ BT474 mouse xenograft model,
combinations of lapatinib and various chemotherapy agents
(e.g. paclitaxel, docetaxel and vinorelbine) have resulted in
signiﬁcantly greater tumor growth inhibition than that
achieved with chemotherapy agents alone (72). In addition,
synergy between the lapatinib derivative, GW282974X and
the capecitabine metabolite, 50-deoxy-5-ﬂurouridine, has
been demonstrated in vitro (73). Preclinical studies have
also shown the beneﬁts of partnering lapatinib with non-
chemotherapy agents that target pathways different to the
ErbB2 pathway. As described in previous sections, lapati-
nib has been shown to act synergistically with endocrine
treatments, such as tamoxifen and fulvestrant (60–62).
Targeting the same pathway, but in different ways has also
proven beneﬁcial. Lapatinib, which targets both the ErbB1
and ErbB2 intracellular tyrosine kinase domain, has shown
synergy in vitro with trastuzumab, which targets the ErbB2
extracellular domain, in the ErbB2-overexpressing
MDA-MB-361 breast cancer cell line (22). The positive
results from these preclinical studies provided the scientiﬁc
justiﬁcation for investigating lapatinib combination therapy
in clinical trials.
CLINICAL EVIDENCE:C OMBINATION THERAPY WITH LAPATINIB
The encouraging results from preclinical studies with lapati-
nib combination therapy are being complemented by positive
efﬁcacy and safety results from completed (Table 1)a n d
ongoing (Table 3) clinical trials. In addition to trials using
lapatinib plus capecitabine combination therapy, clinical
trials of lapatinib and other chemotherapy agents have also
had positive results. For example, lapatinib plus paclitaxel
combination therapy in patients with ErbB2þ breast cancer
resulted in a signiﬁcant increase in TTP, compared with
paclitaxel alone (EGF30001 study; Table 1). The most
common adverse events (e.g. alopecia, rash and diarrhea)
were expected and manageable (74). The availability of a
large number of other effective chemotherapeutic agents for
metastatic breast cancer and the lack of overlapping toxici-
ties has allowed the development of ongoing clinical trials
that combine lapatinib with other chemotherapy agents, such
as docetaxel, doxorubicin, epirubicin, vinorelbine and temo-
zolamide (Table 3). Promising efﬁcacy and safety results
have also been achieved in clinical trials of lapatinib and
non-chemotherapy agents. Signiﬁcant increases in PFS have
been achieved when lapatinib has been partnered with letro-
zole (EGF30008) (66) or with trastuzumab (EGF104900)
(Table 1)( 35,42); there were no unexpected adverse events
with either regimen and each regimen was well-tolerated.
Interest in the potential role of vascular endothelial growth
factor (VEGF) in ErbB2þ breast cancer has also led to clini-
cal trials of lapatinib and non-chemotherapy agents that
target VEGF or the VEGF receptor. A combination of lapati-
nib plus the VEGF receptor inhibitor, pazopanib, was associ-
ated with a signiﬁcant increase in the proportion of patients
who were progression-free at 12 weeks, compared with the
proportion of patients treated with lapatinib alone
(VEG20007) (75). Encouraging results were also obtained
for PFS at 12 weeks in a single-arm clinical trial of lapatinib
plus the anti-VEGF antibody, bevacizumab (EGF103890)
(76). These combination regimens were well-tolerated and
adverse events were consistent with expectations.
CONCLUSION
The management of patients with ErbB2þ breast cancer pre-
sents a number of challenges for clinicians in Asia,
especially given the increasing incidence of breast cancer in
Asia and the adverse clinical consequences of ErbB2þ
breast cancer. Of particular clinical concern are challenges
such as trastuzumab therapy failure, the development of
CNS metastases, chemotherapy-related toxicity and selecting
the most appropriate partners for combination therapy.
Preclinical and clinical evidence suggests that lapatinib may
help address these clinical challenges. Preclinical and clini-
cal studies have shown that lapatinib is effective in inhibiting
the growth of ErbB2þ tumors, including trastuzumab-
resistant tumors. Notably, lapatinib plus capecitabine is
approved for the treatment of patients with ErbB2þ locally
1010 Lapatinib therapy for ErbB2þ breast canceradvanced or metastatic breast cancer who develop progress-
ive disease after treatment with trastuzumab-based regimens.
Clinical studies have also shown that lapatinib, in combi-
nation with hormonal agents (e.g. letrozole), may provide a
chemotherapy-free treatment option for postmenopausal
patients with ERþ/ErbB2þ metastatic breast cancer. More
recently, promising results have emerged on the use of lapa-
tinib to prevent and treat CNS metastases and on the synergy
that may be achieved when lapatinib is combined with che-
motherapeutic and non-chemotherapeutic agents for the
treatment of ErbB2þ breast cancer. The number and nature
of ongoing studies with lapatinib highlight the strong inter-
national interest in gaining further insight into how lapatinib
may enhance the future management of ErbB2þ breast
cancer. Nevertheless, considering the existing evidence base
and our own clinical experience, we believe that lapatinib is
a clinically effective and well-tolerated targeted oral therapy
that clinicians in Asia, and around the world, can use judi-
ciously to enhance their current management of patients with
ErbB2þ breast cancer.
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